Abbott Shaves U.S. Pharma Costs With Restructuring

Abbott plans to eliminate 1,900 positions, mainly within commercial and manufacturing, in a restructuring that will yield pre-tax savings of $200 million.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet